Last year, a little-known Chinese startup took center stage at the American Society for Gene and Cell Therapy annual convention in New Orleans. Speaking before a sprawling conference hall for the presidential symposium, HuidaGene CEO Alvin Luk presented data from one of the world’s first trials to test if CRISPR gene editing could treat children…
NKGen Biotech (OTC: NKGN), a clinical-stage biotech company, will present at the 3rd China Great Bay Cell and Gene Therapy Forum in Guangzhou on September 25-26, 2025. CEO Paul Y. Song will discuss their investigational NK cell therapy, troculeucel, for neurodegenerative diseases. The presentation will take place…
WASHINGTON (AP) — Drugmaker Sarepta Therapeutics (SRPT) said late Friday it won’t comply with a request from the Food and Drug Administration to halt all shipments of its gene therapy following the death of a third patient receiving one of its treatments for muscular dystrophy. The highly unusual move is a latest in a string…